Middle East & Africa Infectious Disease In vitro Diagnostics Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Middle East & Africa Infectious Disease In vitro Diagnostics Market size is expected to reach US$ 2,391.5 Million by 2031 from US$ 1,526.0 Million in 2024. The market is estimated to record a CAGR of 6.7% from 2025 to 2031.

Executive Summary and Middle East & Africa Infectious Disease In vitro Diagnostics Market Analysis:

The market for in vitro diagnostics (IVD) of infectious diseases in the Middle East & Africa, particularly in the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa, is expected to grow to a great extent in the next few years. The main factors of this growth will be the rapid development of healthcare, government initiatives that are friendly to the industry, and stronger international partnerships aimed at better diagnostics. The two countries, Saudi Arabia and the UAE, are the main beneficiaries of this growth to which they have discovered a way to stay ahead by investing in healthcare and tech upgrades. On the other hand, South Africa, through the increasing number of new products in the market, public-private partnerships and the government's support for healthcare innovation, is allowing the market to be more and more developed. Besides, the fast-growing infectious diseases' rates and the demand for IVD solutions that are economically viable, dependable, and quick are making the whole region wake up to the importance of diagnostics. Not to mention, the continuous upgrading of the healthcare industry and the emphasis on the early detection of illnesses are expected to even speed up the use of in vitro diagnostics technology across the Middle East & Africa.

Middle East & Africa Infectious Disease In vitro Diagnostics Market: Strategic Insights

Middle East & Africa Infectious Disease In vitro Diagnostics Market Segmentation Analysis:

• By Applications, the Middle East & Africa Infectious Disease In vitro Diagnostics Market is segmented into HIV or AIDS, Tuberculosis, Hepatitis B and C, Malaria, and Others. Hepatitis B and C held the largest share of the market in 2024.
• By End User, the Middle East & Africa Infectious Disease In vitro Diagnostics Market is segmented into Hospitals and Clinics, Diagnostic Laboratories, Blood Bank, and Others. Hospitals and Clinics held the largest share of the market in 2024.

Middle East & Africa Infectious Disease In vitro Diagnostics Market Players Density: Understanding Its Impact on Business Dynamics

The Middle East & Africa Infectious Disease In vitro Diagnostics Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Middle East & Africa Infectious Disease In vitro Diagnostics Market Outlook

As per the World Health Organization (WHO), tuberculosis (TB) affects 10 million people globally each year. Even though TB can be both prevented and cured, it still claims 1.5 million lives annually, making it among the leading infectious causes of death worldwide. The majority of TB cases occur in low- and middle-income countries, though the disease is found across the globe. In alignment with global health trends, the prevalence of HIV continues to escalate worldwide. According to data from the World Health Organization, an estimated 39.9 million individuals were living with HIV as of the end of 2023, with projections ranging from 36.1 to 44.6 million. Approximately 0.6% of the global adult population aged 15-49 years is affected, although the magnitude and implications of the epidemic vary substantially across different countries and regions.

Furthermore, increasing fungal infections are one of the major concerns among a large population base globally, affecting millions. According to the Global Action Fund for Fungal Infections (GAFFI) 2024, more than 80 million people are at high risk of developing fungal disease every year, and approximately 6.55 million patients develop life-threatening fungal infections, of which 3.75 million people die annually. Thus, the growing cases of infectious diseases create a significant need for in vitro diagnosis to detect diseases and infections before proceeding with the desired treatment. Further, the escalating prevalence of HIV, hepatitis, tuberculosis, influenza, and new viral infections has intensified the demand for rapid and precise diagnostic solutions. Innovations in molecular diagnostics, better point-of-care testing, and greater emphasis on early detection and disease surveillance are collectively driving the adoption of in vitro diagnostics methodologies across both developed and emerging healthcare markets.

Middle East & Africa Infectious Disease In vitro Diagnostics Market Country Insights

By country, the Middle East & Africa Infectious Disease In vitro Diagnostics Market is segmented into South Africa, Saudi Arabia, the United Arab Emirates, and the Rest of Middle East & Africa. Saudi Arabia held the largest share in 2024.

The market for infectious disease in vitro diagnostics in Saudi Arabia is set to grow at a steady rate, with growing healthcare investment moving in line with the Kingdom's Vision 2030. Between 2022 and 2025, health expenditure is expected to increase by 3% on a year-on-year basis to finance the development of public hospitals, clinical labs, and modernized diagnostic facilities throughout the Kingdom.

With rising investments from both public and private sectors, the demand for IVD solutions-particularly for infectious diseases and oncology-is accelerating. Under Vision 2030, the healthcare system is undergoing a strategic decentralization, shifting diagnostic services from tertiary hospitals to primary and community care centers. This transition is designed to broaden access and facilitate earlier detection of critical health conditions.

Despite progress, diagnostic coverage for essential infectious diseases remains a persistent challenge. Data from the Coalition for Global Hepatitis Elimination reveals that in 2022, only 10.45% of hepatitis B cases and 43% of hepatitis C cases were diagnosed. Meanwhile, the World Malaria Report 2024 continues to monitor indigenous malaria cases as Saudi Arabia advances toward its E-2025 elimination targets.

This evolving landscape presents robust opportunities for innovation in laboratory automation, point-of-care diagnostics, and molecular testing technologies, positioning Saudi Arabia as a growing hub for diagnostic advancement.

Middle East & Africa Infectious Disease In vitro Diagnostics Market Company Profiles

Some of the key players operating in the market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sysmex Corp, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, Bruker Corp, QuidelOrtho Corp, Becton, Dickinson and Co, and Danaher Corp.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Middle East & Africa Infectious Disease In vitro Diagnostics Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise